Truist started protection on Edgewise Rehabs Inc EWTX with a Buy ranking and also a cost target of $25.
The expert keeps in mind motivating information from lead medicine EDG-5506 in Becker Muscle Dystrophy (BMD), recommending an advantage to muscular tissue injury received over 6 months.
The business is progressing the CANYON test reviewing EDG-5506 in people with BMD. CANYON will certainly examine the result of EDG-5506 over twelve month on safety and security, pharmacokinetics (PK), biomarkers, and also practical procedures
Edgewise Rehabs anticipates to modify the CANYON research study to consist of a possibly registration-enabling accomplice in 2H of 2023.
The business is reviewing EDG-5506 in Duchenne muscle dystrophy (DMD). LYNX Stage 2 test is continuous, with acting information anticipated in Q4 of 2023.
The expert composes that EDG-5506 has the prospective to end up being standard-of-care in BMD and also improve effectiveness as a combination companion with various techniques in DMD.
While preclinical & & very early scientific information have actually been motivating, long-lasting information from Ph1b & & Ph2 information are most likely required to increase capitalist self-confidence, composes the expert.
With information readouts anticipated over the following 12-18 months, Truist sees a desirable risk-reward account for the supply, with a prospective advantage of 50% -200%.
Rate Activity: EWTX shares are up 11.20% at $9.75 on the last check Monday.
